Stocks · News reference

BMO Capital Initiates Coverage On Prime Medicine with Outperform Rating, Announces Price Target of $9

Aug 19, 2026, 10:21 AMBenzinga Newsdesk

BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $9.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 19, 2026, 10:21 AM
Checked: Aug 19, 2026, 10:21 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 19, 2026, 2:14 PMBenzinga Newsdesk
Prime Medicine shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a $9 price target.
Read original at benzinga
PRME
BenzingaAug 19, 2026, 2:08 PMAvi Kapoor
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
Read original at benzinga
ARIS ASTL BNTX COTY CRSP
BenzingaAug 10, 2026, 10:25 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Read original at benzinga
PRME